Search clinical trials for: Cabozantinib S-malate

Total 4426 results

University of Washington
National Cancer Institute (NCI); Prostate Cancer Foundation

Terminated

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Recurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)
Exelixis

Completed

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage I Thyroid Gland Papillary Carcinoma | Stage II Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Stage I Thyroid Gland... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Soft Tissue Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Osteosarcoma | Ewing Sarcoma | Recurrent Renal Cell Carcinoma | Refractory Malignant Solid Neoplasm | Rhabdomyosarcoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma

United States
Wuerzburg University Hospital

Recruiting

Cabozantinib in Advanced Adrenocortical Carcinoma (CaboACC)

Adrenocortical Carcinoma

Germany
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

Recurrent Ewing Sarcoma | Recurrent Osteosarcoma | Stage III Osteosarcoma AJCC v7 | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma | Metastatic Ewing Sarcoma | Unresectable Ewing Sarcoma | Unresectable Osteosarcoma

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

Metastatic Adrenal Gland Pheochromocytoma | Locally Advanced Paraganglioma | Metastatic Paraganglioma | Unresectable Adrenal Gland Pheochromocytoma | Unresectable Paraganglioma | Regional Adrenal Gland Pheochromocytoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7 | Endometrial Adenosquamous... and other conditions

United States, Canada
National Cancer Institute (NCI)

Completed

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Malignant Solid Neoplasm | Recurrent Thyroid Gland Carcinoma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Thyroid Gland Medullary Carcinoma

United States, Canada
National Cancer Institute (NCI)

Completed

Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus

HIV Infection | Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm

United States
University of Washington
Exelixis

Active, not recruiting

Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

Stage I Soft Tissue Sarcoma of the Trunk and Extremities | Stage II Soft Tissue Sarcoma of the Trunk and Extremities | Sarcoma of the Extremity | Stage IA Soft Tissue Sarcoma of the Trunk and Extremities | Stage IB Soft Tissue Sarcoma of the Trunk and Extremities

United States
University of Washington
Exelixis

Terminated

Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

Advanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma

United States
Alliance for Clinical Trials in Oncology

Not yet recruiting

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma
National Cancer Institute (NCI)

Completed

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
National Cancer Institute (NCI)

Completed

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States
National Cancer Institute (NCI)

Completed

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Recurrent Lung Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study

Low Anterior Resection Syndrome | Malignant Uterine Neoplasm | Rectal Carcinoma | Malignant Ovarian Neoplasm | Malignant Pelvic Neoplasm | Malignant Anal Neoplasm | Malignant Bladder Neoplasm | Malignant Cervical Neoplasm | Malignant Prostate Neoplasm | Malignant Vaginal Neoplasm | Malignant Vulvar Neoplasm

United States
Barbara Ann Karmanos Cancer Institute

Completed

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Bologna
Ipsen; Bioikos Ambiente Srl; AOU S.Orsola Malpighi-Unit of Oncologic Molecular... and other collaborators

Unknown

Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)

Non Small Cell Lung Cancer

Italy
Exelixis

Completed

Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer

Cancer | NSCLC | Solid Tumors

Japan
OHSU Knight Cancer Institute
Oregon Health and Science University

Withdrawn

Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma
National University of Malaysia

Recruiting

Comparison of Modified Vacuum-formed Retainers Versus Hawley Retainer

Clinical Trial | Orthodontic Retainers

Malaysia
University of Utah
National Cancer Institute (NCI)

Recruiting

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Karsten Gavenis

Recruiting

A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 (CABONEN)

Neuroendocrine Tumors | Neuroendocrine Carcinoma

Germany, Austria
Institut für Klinische Krebsforschung IKF GmbH...
Ipsen

Recruiting

Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

Hepatocellular Carcinoma Non-resectable | Metastatic Hepatocellular Carcinoma

Germany
Istituto Oncologico Veneto IRCCS

Active, not recruiting

Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma (ZEBRA)

Renal Cell Carcinoma

Italy
Spanish Oncology Genito-Urinary Group
Apices Soluciones S.L.

Completed

Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study (CABOMAYOR)

Old Age; Debility | Renal Carcinoma Metastatic

Spain
Stephen Chan Lam

Active, not recruiting

Cabozantinib in Hepatocellular Carcinoma

HCC

Korea, Republic of, Hong Kong
Exelixis

Approved for marketing

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Medullary Thyroid Cancer

United States
University of Leipzig

Recruiting

Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors (CaPture)

Hepatocellular Carcinoma

Germany
Centre Leon Berard

Recruiting

Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases (CABRAMET)

Metastatic Renal Cell Carcinoma

France
Centre Francois Baclesse

Completed

Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure (CABOCOL-01)

Advanced/Metastatic Cervical Cancer

France
Spanish Oncology Genito-Urinary Group
Ipsen; Syntax for Science, S.L

Completed

Spanish Real-World Evidence Cabozantinib (SRWEC)

Renal Cell Carcinoma

Spain
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Completed

caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (BONSAI)

Collecting Duct Carcinoma (Kidney)

Italy
Dana-Farber Cancer Institute

Completed

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Carcinoid Tumor | Pancreatic Neuroendocrine Tumor

United States
University of Campania "Luigi Vanvitelli"

Active, not recruiting

caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer. (ABACO)

Refractory Colorectal Adenocarcinoma

Italy
Hospices Civils de Lyon

Completed

Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) (CLERANCE)

Hepatocellular Carcinoma

France
Massachusetts General Hospital

Completed

Cabozantinib in Advanced Solid Malignancies

Lung Cancer | Solid Tumor (Not Breast or Prostate Cancers)

United States
University of Michigan Rogel Cancer Center
Exelixis

Terminated

Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

Prostate Cancer Metastatic

United States
Dana-Farber Cancer Institute

Completed

Cabozantinib for Metastatic Triple Negative BrCa

Breast Cancer

United States
Jennifer King
Exelixis

Recruiting

A Phase II Trial of Cabozantinib With Patients With Refractory GCTs

Ovarian Germ Cell Tumor | Seminoma | Germ Cell Tumor | Non-seminomatous Germ Cell Tumor

United States
Memorial Sloan Kettering Cancer Center
Exelixis

Recruiting

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Non-Small Cell Lung Cancer

United States
University of Michigan Rogel Cancer Center
Exelixis

Active, not recruiting

Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy

Advanced Adult Hepatocellular Carcinoma

United States
Thomas Jefferson University

Active, not recruiting

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Differentiated Thyroid Cancer (DTC) | Poorly Differentiated Thyroid Cancer

United States
Fondazione Ricerca Traslazionale

Unknown

CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation (CABinMET)

Non-Small Cell Lung Cancer

Italy
Massachusetts General Hospital
Exelixis

Completed

Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia

United States
Radboud University Medical Center
Ipsen

Terminated

Cabozantinib in Advanced Salivary Gland Cancer Patients (Cabo ASAP)

Salivary Gland Cancer

Netherlands

Search clinical trials for: Cabozantinib S-malate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations